Cardinal Health Inc. (CAH)
Cardinal Health distributes medicines and medical products and sells the services that move them, supplying hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. An Ohio corporation formed in 1979, it reports two segments, Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution, with three smaller operating segments grouped as Other. Its financial year ends on 30 June.
Compare with another name What $10,000 in Cardinal Health became Open in your desk ↗
Latest results
this quarterthe same quarter a year earlierHover a bar for its figure.
this yearthe year beforeHover a bar for its figure.
The years before, in words
Cardinal Health (CAH) reported revenue of $254.2 billion for fiscal 2026, the year ended 30 June 2026, up 14.2% on the year before. Net income was $1.7 billion and diluted earnings per share $7.23. Revenue was $222.6 billion in fiscal 2025, $226.8 billion in fiscal 2024, $205.0 billion in fiscal 2023 and $181.4 billion in fiscal 2022. Net income in the same years was $1.6 billion, $852 million, $330 million and a loss of $938 million. Over the twelve months to 30 September 2026, Cardinal Health reported revenue of $257.8 billion and net income of $1.8 billion. Revenue grew 9.4% a year, compounded, over the five years to fiscal 2026. Cardinal Health declared $2.04 a share in dividends over the last four quarters and had 231 million shares outstanding at the latest filed count. At 30 September 2026 it carried $8.8 billion of debt and $5.3 billion of cash. At the close of 6 November 2026 the market cap of Cardinal Health was $62.9 billion, 35.1 times its earnings over the last twelve months.Ratios
From the filings
ROEn/a
ROCEn/a
Operating margin1.0%
Net margin0.7%
FCF margin1.9%
Interest cover7.9x
Debt to equityn/a
Cash conversion3.08x
Share count, last 12 months-2.7%
Sales CAGR, 3 years7.4%
Profit CAGR, 3 years73.2%
EPS, TTM$7.74
At the close of 6 November 2026
Price$271.95
Market cap$62.9 billion
Stock P/E35.1x
Price to bookn/a
EV / EBITDA18.1x
Dividend yield0.8%
Market cap / sales0.24x
52-week high$271.95
52-week low$182.50
Price, 1 year37.4%
Price CAGR, 3 years38.2%
Price CAGR, 5 years40.6%
29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Cardinal Health Inc.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.CAHgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.Quarterly results
| Q2 FY2022 | Q3 FY2022 | Q4 FY2022 * | Q1 FY2023 † | Q2 FY2023 † | Q3 FY2023 † | Q4 FY2023 * † | Q1 FY2024 † | Q2 FY2024 † | Q3 FY2024 † | Q4 FY2024 * † | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 * | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45,457 | 44,836 | 47,103 | 49,603 | 51,469 | 50,487 | 53,453 | 54,650 | 57,445 | 54,911 | 59,708 | 52,277 | 55,264 | 54,878 | 60,159 | 64,009 | 65,627 | 60,940 | 63,672 | 67,513 |
| Cost of revenue | 43,841 | 43,154 | 45,498 | 47,989 | 49,806 | 48,702 | 51,626 | 52,995 | 55,599 | 52,964 | 57,855 | 50,375 | 53,323 | 52,755 | 57,957 | 61,690 | 63,230 | 58,442 | 61,112 | 64,917 |
| Gross profit | 1,616 | 1,682 | 1,605 | 1,596 | 1,684 | 1,810 | 1,784 | 1,743 | 1,854 | 1,935 | 1,882 | 1,902 | 1,941 | 2,123 | 2,202 | 2,319 | 2,397 | 2,498 | 2,560 | 2,596 |
| Gross margin | 4% | 4% | 3% | 3% | 3% | 4% | 3% | 3% | 3% | 4% | 3% | 4% | 4% | 4% | 4% | 4% | 4% | 4% | 4% | 4% |
| SG&A | 1,151 | 1,137 | 1,155 | 1,197 | 1,179 | 1,172 | 1,252 | 1,186 | 1,268 | 1,269 | 1,277 | 1,277 | 1,306 | 1,315 | 1,484 | 1,461 | 1,504 | 1,542 | 1,625 | 1,595 |
| Operating income | -950 | -97.0 | 36.0 | 123 | -86.0 | 604 | 111 | -32.0 | 505 | 369 | 401 | 568 | 549 | 730 | 428 | 668 | 707 | 509 | 729 | 753 |
| Operating margin | -2% | -0% | 0% | 0% | -0% | 1% | 0% | -0% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Interest expense | 37.0 | 38.0 | 34.0 | 24.0 | 24.0 | 26.0 | 10.0 | 11.0 | 3.0 | 28.0 | 9.0 | 32.0 | 35.0 | 74.0 | 74.0 | 80.0 | 88.0 | 101 | 79.0 | 73.0 |
| Pre-tax income | -973 | -137 | -28.0 | 96.0 | -104 | 576 | 95.0 | -44.0 | 512 | 342 | 391 | 541 | 511 | 665 | 384 | 598 | 630 | 392 | 554 | 688 |
| Tax rate | n/a | n/a | n/a | -3% | n/a | 36% | 161% | n/a | 28% | 23% | 40% | 23% | 22% | 24% | 37% | 24% | 25% | 3% | 28% | 19% |
| Net income | 49.0 | -1,391 | 138 | 98.0 | -77.0 | 365 | -56.0 | -12.0 | 368 | 261 | 235 | 416 | 400 | 506 | 239 | 450 | 467 | 399 | 398 | 554 |
| Net margin | 0% | -3% | 0% | 0% | -0% | 1% | -0% | -0% | 1% | 0% | 0% | 1% | 1% | 1% | 0% | 1% | 1% | 1% | 1% | 1% |
| Diluted EPS | $0.17 | -$5.05 | $0.59 | $0.40 | -$0.30 | $1.41 | -$0.51 | -$0.05 | $1.50 | $1.07 | $0.96 | $1.70 | $1.65 | $2.10 | $1.00 | $1.88 | $1.97 | $1.69 | $1.70 | $2.38 |
| Operating cash flow | 1,195 | -419 | 2,992 | 23.0 | 597 | 1,361 | 858 | 528 | 1,189 | -49.0 | 2,077 | -1,647 | -400 | 2,917 | 1,527 | 973 | 686 | 1,823 | 1,692 | 1,398 |
| Capital expenditure | 74.0 | 82.0 | 164 | 70.0 | 85.0 | 109 | 217 | 92.0 | 114 | 112 | 193 | 90.0 | 99.0 | 126 | 232 | 108 | 131 | 146 | 264 | 157 |
| Free cash flow | 1,121 | -501 | 2,828 | -47.0 | 512 | 1,252 | 641 | 436 | 1,075 | -161 | 1,884 | -1,737 | -499 | 2,791 | 1,295 | 865 | 555 | 1,677 | 1,428 | 1,241 |
| Buybacks | 300 | 200 | 0.0 | 1,000 | 250 | 250 | 500 | 500 | 250 | 0.0 | 0.0 | 375 | 15.0 | 375 | 0.0 | 375 | 383 | 250 | 350 | 500 |
| Dividends paid | 140 | 136 | 134 | 142 | 129 | 128 | 126 | 131 | 124 | 122 | 122 | 128 | 122 | 124 | 120 | 129 | 122 | 120 | 120 | 126 |
| Shares outstanding | 277m | 272m | 273m | 262m | 258m | 255m | 251m | 246m | 243m | 244m | 244m | 242m | 242m | 239m | 239m | 238m | 235m | 234m | 233m | 231m |
| Filing | 10-Q | 10-Q | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Income statement (profit and loss)
Play it forward: change any box and its column follows; every box opens at the company's own record, shown under the row's name, and says when you set it outside every year in the table.
Read more
Each column runs from the last twelve months as filed to the year chosen in its heading, at a yearly rate. Sales growth starts at the company's own five-year rate and eases a third of the way each year toward the median of the 60 peers in Wholesale (8.4% a year), because a rate far from the rest rarely lasts. Before you open a year, the strip reads today's price backwards: the yearly sales growth that brings EPS, at the company's own margins, tax and share count, to today's price at the median P/E of the 45 peers in Wholesale (20.1). Low, middle, high opens three columns for one year: the low and high cases take the company's own weaker and stronger years in the table (the lower and upper quarter of its yearly sales growth and operating margin) and the lower and higher of today's P/E and its peers'; the middle is the boxes as they open. Net income keeps the share that went to minority holders; EPS is net income over the diluted shares, on the same basis as the EPS in the table. The price is that year's EPS at the P/E you set, and the yearly return runs from today's price to the year's end. These are your assumptions and your arithmetic, not an estimate of ours. The link carries your columns, so you can send the forecast to someone.| FY2008 | FY2009 † | FY2010 † | FY2011 † | FY2012 † | FY2013 † | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 † | FY2022 † | FY2023 † | FY2024 | FY2025 | FY2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 87,408 | 95,992 | 98,503 | 102,644 | 107,552 | 101,093 | 91,084 | 102,531 | 121,546 | 129,976 | 136,809 | 145,534 | 152,922 | 162,467 | 181,364 | 205,012 | 226,827 | 222,578 | 254,248 | 257,752 |
| Cost of revenue | 83,631 | 92,244 | 94,722 | 98,482 | 103,011 | 96,172 | 85,923 | 96,819 | 115,003 | 123,432 | 129,628 | 138,700 | 146,054 | 155,689 | 174,819 | 198,123 | 219,413 | 214,410 | 244,474 | 247,701 |
| Gross profit | 3,777 | 3,748 | 3,781 | 4,162 | 4,541 | 4,921 | 5,161 | 5,712 | 6,543 | 6,544 | 7,181 | 6,834 | 6,868 | 6,778 | 6,484 | 6,874 | 7,414 | 8,168 | 9,774 | 10,051 |
| Gross margin | 4.3% | 3.9% | 3.8% | 4.1% | 4.2% | 4.9% | 5.7% | 5.6% | 5.4% | 5.0% | 5.2% | 4.7% | 4.5% | 4.2% | 3.6% | 3.4% | 3.3% | 3.7% | 3.8% | 3.9% |
| Selling, general and administrative | 2,341 | 2,320 | 2,397 | 2,528 | 2,677 | 2,875 | 3,028 | 3,240 | 3,648 | 3,775 | 4,596 | 4,480 | 4,572 | 4,533 | 4,512 | 4,800 | 5,000 | 5,382 | 6,132 | 6,266 |
| Operating income | 1,392 | 1,287 | 1,307 | 1,514 | 1,792 | 996 | 1,885 | 2,161 | 2,459 | 2,120 | 126 | 2,060 | -4,098 | 472 | -607 | 752 | 1,243 | 2,275 | 2,613 | 2,698 |
| Operating margin | 1.6% | 1.3% | 1.3% | 1.5% | 1.7% | 1.0% | 2.1% | 2.1% | 2.0% | 1.6% | 0.1% | 1.4% | -2.7% | 0.3% | -0.3% | 0.4% | 0.5% | 1.0% | 1.0% | 1.0% |
| Interest expense | 136 | 114 | 113 | 93.0 | 95.0 | 123 | 133 | 141 | 178 | 201 | 329 | 294 | 238 | 180 | 147 | 84.0 | 51.0 | 215 | 348 | 341 |
| Pre-tax income | 1,295 | 1,160 | 1,212 | 1,518 | 1,698 | 888 | 1,798 | 1,967 | 2,276 | 1,924 | -228 | 1,751 | -3,772 | 323 | -784 | 663 | 1,201 | 2,101 | 2,174 | 2,264 |
| Income tax | 448 | 402 | 625 | 552 | 628 | 553 | 635 | 755 | 845 | 630 | -487 | 386 | -79.0 | -289 | 153 | 332 | 348 | 532 | 469 | 457 |
| Effective tax rate | 34.6% | 34.6% | 51.6% | 36.4% | 37.0% | 62.3% | 35.3% | 38.4% | 37.1% | 32.7% | n/a | 22.0% | n/a | -89.5% | n/a | 50.1% | 29.0% | 25.3% | 21.6% | 20.2% |
| Net income | 1,301 | 1,152 | 642 | 959 | 1,069 | 334 | 1,166 | 1,215 | 1,427 | 1,288 | 256 | 1,363 | -3,696 | 611 | -938 | 330 | 852 | 1,561 | 1,714 | 1,818 |
| Net margin | 1.5% | 1.2% | 0.7% | 0.9% | 1.0% | 0.3% | 1.3% | 1.2% | 1.2% | 1.0% | 0.2% | 0.9% | -2.4% | 0.4% | -0.5% | 0.2% | 0.4% | 0.7% | 0.7% | 0.7% |
| Diluted EPS | n/a | $3.18 | $1.77 | $2.72 | $3.06 | $0.97 | $3.38 | $3.62 | $4.32 | $4.03 | $0.81 | $4.53 | -$12.61 | $2.08 | -$3.37 | $1.26 | $3.45 | $6.45 | $7.23 | $7.74 |
| Filing | 10-K/A | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
From each year's 10-K, linked; TTM is the last four quarters.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.Revenue by segment FY2010 to FY2026
| FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Specialty Solutions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 164,596 | 188,814 | 210,019 | 204,644 | 234,833 | 92.3% |
| GMPD | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 13,280 | 12,222 | 12,381 | 12,636 | 12,719 | 5.0% |
| Other Operating Segment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 3,518 | 4,021 | 4,512 | 5,382 | 6,792 | 2.7% |
| Medical | 8,750 | 8,922 | 9,642 | 10,060 | 10,962 | 11,395 | 12,430 | 13,524 | 15,581 | 15,633 | 15,444 | 16,687 | n/a | n/a | n/a | n/a | n/a | n/a |
| Pharmaceutical | 89,790 | 93,744 | 97,925 | 91,097 | 80,110 | 91,116 | 109,131 | 116,463 | 121,241 | 129,917 | 137,495 | 145,796 | n/a | n/a | n/a | n/a | n/a | n/a |
| Corporate | -37 | -22 | -15 | -64 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pharmaceutical and Specialty Solutions FY2022 to FY2026GMPD FY2022 to FY2026Other Operating Segment FY2022 to FY2026Pharmaceutical FY2010 to FY2021Medical FY2010 to FY2021
$ billion; hover a block for its figure and share; the figure over a bar is its parts, before the lines named below; a part named with years is one the company split its revenue into only then
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in. Corporate is the company's own eliminations and corporate items, which take the parts to revenue: shown as filed, with no share and no block in the chart.Profit by segment FY2010 to FY2026
The operating profit each segment reports. Costs Cardinal Health does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.
| FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | Margin FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Specialty Solutions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1,643 | 1,881 | 2,015 | 2,258 | 2,783 | 1.2% |
| GMPD | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -64 | -147 | 92 | 135 | 258 | 2.0% |
| Other Operating Segment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 390 | 396 | 423 | 516 | 707 | 10.4% |
| Medical | 429 | 373 | 332 | 372 | 444 | 433 | 457 | 572 | 662 | 576 | 663 | 577 | n/a | n/a | n/a | n/a | n/a | n/a |
| Pharmaceutical | 1,011 | 1,329 | 1,558 | 1,734 | 1,745 | 2,094 | 2,488 | 2,187 | 1,992 | 1,834 | 1,753 | 1,684 | n/a | n/a | n/a | n/a | n/a | n/a |
Pharmaceutical and Specialty Solutions FY2022 to FY2026Pharmaceutical FY2010 to FY2021GMPD FY2022 to FY2026Medical FY2010 to FY2021Other Operating Segment FY2022 to FY2026
$ million; the figure over a bar is all the segments together; a year a segment lost money, it hangs below the line. Hover a block for its profit, sales and margin.
FY2026Share of salesShare of profit
Pharmaceutical and Specialty Solutions92%74%
GMPD5%7%
Other Operating Segment3%19%
Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.Revenue by region FY2012 to FY2026
| FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 105,205 | 97,994 | 87,449 | 98,435 | 116,864 | 125,017 | 132,539 | 141,479 | 148,707 | 157,756 | 179,471 | 203,440 | 225,231 | 220,993 | 252,639 | 99.3% |
| International | 2,347 | 3,099 | 3,635 | 4,096 | 4,682 | 4,970 | 4,283 | 4,071 | 4,232 | 4,727 | 1,923 | 1,617 | 1,681 | 1,669 | 1,705 | 0.7% |
United StatesInternational
$ billion; hover a block for its figure and share
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.First forecast against the result
Cardinal Health's adjusted EPS landed at or above the top of the range in 2, inside it in 1 and under it in 2 of the 5 years shown (FY2014 to FY2020).
- At or above the top of the range
- Inside the range
- Under the range
Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.
| Fiscal year | First forecast adjusted EPS | Result |
|---|---|---|
| FY2014 | $3.45 to $3.60 | $3.37 |
| FY2015 | $4.10 to $4.30 | $3.61 |
| FY2018 | $4.85 to $5.10 | $5.00 |
| FY2019 | $4.90 to $5.15 | $5.28 |
| FY2020 | $4.85 to $5.10 | $5.45 |
- FY2027 forecast
- Adjusted EPS $12.40 to $12.60, given 11 August 2026. Its result comes with the fourth-quarter results for FY2027.
- First forecast
- The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
- Result
- The figure the company reported for that year with its next fourth-quarter results.
- Adjusted EPS
- The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
- Years left out
- Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.
Cash flow
Follow the cash: free cash flow, which is operating cash flow less capital expenditure and share-based pay, for five years and after, in today's money.
Read more
The figure a share at the top is what a discounted cash flow calls intrinsic value, worked out on your assumptions. Everything after year five is one sum: the sixth year's cash, growing at the long-run rate every year after, added up and brought back to today's money. Each year runs from the last twelve months as filed. Sales growth opens where Play it forward does: the company's own five-year rate, easing a third of the way each year toward the median of the 60 peers in Wholesale (8.4% a year); change a year and the years after it follow. Operating cash flow, capital expenditure and share-based pay open at the company's own median share of sales over its last five years, shown under each row. Share-based pay is taken off because operating cash flow adds back the shares paid to staff as if they cost nothing; set it to 0 to leave it in. Capital spending counts every capital line the company files in its cash flow, such as equipment it leases to customers, software, wells or property it develops, named under the row, while the Capital expenditure row in the table below stays the one line as filed; buying a business, securities or a finished property is not counted. The discount rate opens at 10%, about what US stocks have returned a year over the long run, so it is the return you give up by holding this company instead of the market; the growth after year five opens at 3%, a little under the US economy's long-run growth in dollars, because no company outgrows it for ever. Net debt is the debt and short-term borrowings less the cash on the latest balance sheet that shows the debt; the figure per share divides what is left by the diluted share count. These are your assumptions and your arithmetic, not an estimate of ours. The link carries them, so you can send them to someone.| FY2008 | FY2009 † | FY2010 † | FY2011 † | FY2012 † | FY2013 † | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 † | FY2022 † | FY2023 † | FY2024 | FY2025 | FY2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,542 | 1,424 | 2,134 | 1,395 | 1,176 | 1,727 | 2,524 | 2,540 | 2,971 | 1,184 | 2,768 | 2,722 | 1,960 | 2,429 | 3,175 | 2,839 | 3,762 | 2,397 | 5,174 | 5,599 |
| Capital expenditure | 156 | 421 | 260 | 291 | 260 | 195 | 249 | 300 | 465 | 387 | 384 | 328 | 375 | 400 | 387 | 481 | 511 | 547 | 649 | 698 |
| Free cash flow | 1,386 | 1,003 | 1,874 | 1,103 | 916 | 1,532 | 2,275 | 2,240 | 2,506 | 797 | 2,384 | 2,394 | 1,585 | 2,029 | 2,788 | 2,358 | 3,251 | 1,850 | 4,525 | 4,901 |
| Free cash flow margin | 1.6% | 1.0% | 1.9% | 1.1% | 0.9% | 1.5% | 2.5% | 2.2% | 2.1% | 0.6% | 1.7% | 1.6% | 1.0% | 1.2% | 1.5% | 1.2% | 1.4% | 0.8% | 1.8% | 1.9% |
| Cash from investing | -726 | -543 | 127 | -2,028 | -377 | -2,375 | -850 | -849 | -4,080 | -405 | -5,608 | 338 | 493 | -378 | 567 | -454 | -1,849 | -5,593 | -2,584 | -2,693 |
| Cash from financing | -803 | -468 | -728 | -193 | -454 | 275 | -710 | 60.0 | -1,139 | 3,746 | -2,276 | -2,293 | -2,200 | -1,317 | -2,463 | -3,051 | -847 | 1,940 | -1,602 | -2,234 |
| Depreciation and amortisation | 220 | 226 | 254 | 313 | 325 | 397 | 459 | 451 | 641 | 717 | 1,032 | 1,000 | 913 | 783 | 692 | 692 | 710 | 790 | 956 | 970 |
| Share-based compensation | 108 | 110 | 100 | 80.0 | 85.0 | 93.0 | 96.0 | 110 | 111 | 96.0 | 85.0 | 82.0 | 90.0 | 89.0 | 81.0 | 96.0 | 121 | 244 | 367 | 230 |
| Buybacks | 1,182 | 0.0 | 230 | 270 | 450 | 450 | 673 | 1,036 | 651 | 600 | 550 | 600 | 350 | 200 | 1,000 | 2,000 | 750 | 765 | 1,358 | 1,483 |
| Dividends paid | 173 | 200 | 253 | 274 | 300 | 353 | 415 | 460 | 512 | 577 | 581 | 577 | 569 | 573 | 559 | 525 | 499 | 494 | 491 | 488 |
| Dividend per share | $0.48 | $0.56 | $0.70 | $0.78 | $0.86 | $1.02 | $1.21 | $1.37 | $1.55 | $1.80 | $1.85 | $1.91 | $1.92 | $1.94 | $1.96 | $1.98 | $2.00 | $2.02 | $2.04 | n/a |
| Diluted shares, weighted | 364m | 362m | 361m | 352m | 349m | 344m | 345m | 335m | 330m | 320m | 315m | 301m | 293m | 294m | 279m | 262m | 247m | 242m | 237m | 233m |
| Shares outstanding at period end | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 231m |
| Filing | 10-K/A | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Cash paid in the year, from the cash flow statement.
Read more
The dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.Balance sheet
| FY2008 | FY2009 † | FY2010 † | FY2011 † | FY2012 † | FY2013 † | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 † | FY2022 † | FY2023 † | FY2024 | FY2025 | FY2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Funded by | ||||||||||||||||||||
| Shareholders' equity | 7,748 | 8,725 | 5,276 | 5,849 | 6,244 | 5,975 | 6,401 | 6,256 | 6,554 | 6,808 | 6,059 | 6,328 | 1,789 | 1,791 | -709 | -2,958 | -3,213 | -2,781 | -2,883 | -3,025 |
| Non-controlling interest | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.0 | 17.0 | 20.0 | 0.0 | 2.0 | 3.0 | 3.0 | 3.0 | 1.0 | 1.0 | 147 | 159 | 159 |
| Redeemable equity | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.0 | 117 | 118 | 12.0 | 0.0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | 3,638 | 2,129 | 2,502 | 2,894 | 3,854 | 3,972 | 5,492 | 5,539 | 10,395 | 9,013 | 8,031 | 6,800 | 6,200 | 5,300 | 4,700 | 5,100 | 8,527 | 8,886 | 8,815 |
| Operating lease liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 341 | 374 | 388 | 375 | 400 | 654 | 861 | n/a |
| Finance lease liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 25.0 | 45.0 | 49.0 | 59.0 | 75.0 | 157 | 140 | n/a |
| Other liabilities | n/a | 12,756 | 12,585 | 14,495 | 15,122 | 15,990 | 15,660 | 18,394 | 21,895 | 22,771 | 24,867 | 26,602 | 31,808 | 36,040 | 38,847 | 41,240 | 42,758 | 46,418 | 50,136 | 53,595 |
| Total liabilities and equity | n/a | 25,119 | 19,990 | 22,846 | 24,260 | 25,819 | 26,033 | 30,142 | 34,122 | 40,112 | 39,951 | 40,963 | 40,766 | 44,453 | 43,878 | 43,417 | 45,121 | 53,122 | 57,299 | 59,544 |
| Owned | ||||||||||||||||||||
| Fixed assets | n/a | 1,464 | 1,469 | 1,512 | 1,551 | 1,489 | 1,459 | 1,506 | 1,796 | 1,879 | 2,487 | 2,356 | 2,366 | 2,360 | 2,361 | 2,462 | 2,529 | 2,858 | 3,031 | 2,999 |
| Goodwill | 2,229 | 2,196 | 2,205 | 3,846 | 3,978 | 4,601 | 4,878 | 5,070 | 7,167 | 7,221 | 8,316 | 8,378 | 8,357 | 7,989 | 5,855 | 4,609 | 4,725 | 9,691 | 11,442 | 11,543 |
| Intangible assets | n/a | 70.4 | 47.8 | 413 | 414 | 973 | 992 | 948 | 2,259 | 1,986 | 3,913 | 3,430 | 2,918 | 2,105 | 1,774 | 1,472 | 1,725 | 2,486 | 2,189 | 2,146 |
| Investments | n/a | 0.0 | 692 | 0.0 | n/a | n/a | 100 | 193 | 200 | 65.0 | n/a | n/a | n/a | n/a | n/a | n/a | 200 | n/a | n/a | n/a |
| Cash and equivalents | 809 | 1,222 | 2,755 | 1,929 | 2,274 | 1,901 | 2,865 | 4,616 | 2,356 | 6,879 | 1,763 | 2,531 | 2,771 | 3,407 | 4,717 | 4,076 | 5,133 | 3,874 | 4,856 | 5,264 |
| Receivables | n/a | 5,215 | 5,171 | 6,156 | 6,355 | 6,304 | 5,380 | 6,523 | 7,405 | 8,048 | 7,800 | 8,448 | 8,264 | 9,103 | 10,561 | 11,108 | 12,084 | 13,242 | 13,815 | 14,542 |
| Inventory | n/a | 6,833 | 6,356 | 7,334 | 7,864 | 8,373 | 8,266 | 9,211 | 10,615 | 11,301 | 12,308 | 12,822 | 13,198 | 14,594 | 15,636 | 16,119 | 14,957 | 16,831 | 17,297 | 18,395 |
| Other assets | n/a | 8,118 | 1,295 | 1,656 | 1,824 | 2,178 | 2,093 | 2,075 | 2,324 | 2,733 | 3,364 | 2,998 | 2,892 | 4,895 | 2,974 | 3,571 | 3,768 | 4,140 | 4,669 | 4,655 |
| Total assets | n/a | 25,119 | 19,990 | 22,846 | 24,260 | 25,819 | 26,033 | 30,142 | 34,122 | 40,112 | 39,951 | 40,963 | 40,766 | 44,453 | 43,878 | 43,417 | 45,121 | 53,122 | 57,299 | 59,544 |
| Filing | 10-K/A | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
At the fiscal year end; the TTM column is the latest quarter end.
Read more
Both totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.Compounded growth
| 10 years | 5 years | 3 years | TTM | |
|---|---|---|---|---|
| Sales growth, compounded | 7.7% | 9.4% | 7.4% | 10.0% |
| Profit growth, compounded | 1.8% | 22.9% | 73.2% | 14.0% |
| Return on equity, average | n/a | n/a | n/a | n/a |
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read more
Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.Questions
What was Cardinal Health's revenue in fiscal 2026?
Cardinal Health (CAH) reported revenue of $254.2 billion for fiscal 2026, the year ended 30 June 2026, up 14.2% on the year before.
How much did Cardinal Health earn in fiscal 2026?
Net income was $1.7 billion for fiscal 2026, and diluted earnings per share $7.23.
What is Cardinal Health's P/E ratio?
At the close of 6 November 2026, Cardinal Health traded at 35.1 times its earnings over the twelve months to 30 September 2026.
What is Cardinal Health's market cap?
The market cap of Cardinal Health was $62.9 billion at the close of 6 November 2026.
Does Cardinal Health pay a dividend?
Yes. Cardinal Health declared $2.04 a share in dividends over the four quarters to 30 September 2026.
Peers: Wholesale
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| McKesson Corp. MCK | $122.5 billion | 27.28 | n/a | 1.6% | 8.2% | n/a | 0.3% |
| W.W. Grainger, Inc. GWW | $67.4 billion | 31.65 | 49.8% | 15.8% | 9.1% | 0.62 | 0.7% |
| Cencora, Inc. COR | $63.6 billion | 24.78 | 86.0% | 0.9% | 5.1% | 3.84 | 0.7% |
| Cardinal Health Inc. CAH | $62.9 billion | 35.14 | n/a | 1.0% | 10.0% | n/a | 0.8% |
| TE Connectivity plc TEL | $59.9 billion | 20.30 | 22.8% | 19.7% | 16.5% | 0.43 | 1.4% |
| Ferguson Enterprises Inc. FERG | $45.2 billion | n/a | n/a | n/a | n/a | 0.79 | 1.4% |
| Sysco Corp. SYY | $37.8 billion | 20.45 | 44.7% | 3.5% | 3.8% | 3.42 | 2.8% |
| US Foods Holding Corp. USFD | $22.9 billion | 29.80 | 18.3% | 3.3% | 3.1% | 1.18 | n/a |
| Reliance, Inc. RS | $21.3 billion | 19.45 | 14.3% | 8.8% | 24.7% | 0.21 | 1.2% |
| TD Synnex Corp. SNX | $17.5 billion | 13.33 | 14.3% | 2.7% | 24.1% | 0.59 | 0.9% |
| Herbalife Ltd. HLF | $1.6 billion | 9.10 | n/a | 9.6% | 6.4% | n/a | n/a |
| NU Skin Enterprises, Inc. NUS | $199 million | n/a | -42.8% | -2.0% | -15.3% | 0.37 | 5.9% |
All 65 in Wholesale
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| McKesson Corp. MCK | $122.5 billion | 27.28 | n/a | 1.6% | 8.2% | n/a | 0.3% |
| W.W. Grainger, Inc. GWW | $67.4 billion | 31.65 | 49.8% | 15.8% | 9.1% | 0.62 | 0.7% |
| Cencora, Inc. COR | $63.6 billion | 24.78 | 86.0% | 0.9% | 5.1% | 3.84 | 0.7% |
| Cardinal Health Inc. CAH | $62.9 billion | 35.14 | n/a | 1.0% | 10.0% | n/a | 0.8% |
| TE Connectivity plc TEL | $59.9 billion | 20.30 | 22.8% | 19.7% | 16.5% | 0.43 | 1.4% |
| Ferguson Enterprises Inc. FERG | $45.2 billion | n/a | n/a | n/a | n/a | 0.79 | 1.4% |
| Sysco Corp. SYY | $37.8 billion | 20.45 | 44.7% | 3.5% | 3.8% | 3.42 | 2.8% |
| US Foods Holding Corp. USFD | $22.9 billion | 29.80 | 18.3% | 3.3% | 3.1% | 1.18 | n/a |
| Reliance, Inc. RS | $21.3 billion | 19.45 | 14.3% | 8.8% | 24.7% | 0.21 | 1.2% |
| TD Synnex Corp. SNX | $17.5 billion | 13.33 | 14.3% | 2.7% | 24.1% | 0.59 | 0.9% |
| Genuine Parts Co. GPC | $16.9 billion | 491.46 | 0.7% | 3.6% | 5.3% | 1.10 | 3.4% |
| Performance Food Group Co. PFGC | $16.9 billion | 42.83 | 7.8% | 1.4% | 5.9% | 1.02 | n/a |
| Wesco International Inc. WCC | $14.2 billion | 18.17 | 14.5% | 5.6% | 13.5% | 1.10 | n/a |
| Watsco Inc. WSO | $12.6 billion | 26.88 | 15.5% | 9.1% | 0.3% | 0.04 | 4.1% |
| Domino's Pizza, Inc. DPZ | $11.0 billion | 18.42 | n/a | 19.7% | 4.5% | n/a | 2.3% |
| Applied Industrial Technologies Inc. AIT | $10.3 billion | 25.08 | 22.5% | 11.2% | 8.5% | 0.15 | 0.7% |
| Henry Schein Inc. HSIC | $9.5 billion | 23.58 | 13.3% | 5.2% | 6.2% | 1.12 | n/a |
| Arrow Electronics, Inc. ARW | $9.2 billion | 9.18 | 14.2% | 3.8% | 32.5% | 0.38 | n/a |
| Core & Main, Inc. CNM | $8.8 billion | 18.92 | 22.6% | 9.6% | -0.5% | 1.21 | n/a |
| Qxo, Inc. QXO | $8.4 billion | n/a | -4.9% | -3.4% | 408.2% | 0.58 | n/a |
| Pool Corp. POOL | $7.6 billion | 19.47 | 32.3% | 10.5% | 2.9% | 0.95 | 2.4% |
| Avnet Inc. AVT | $6.5 billion | 11.90 | 10.7% | 3.3% | 44.3% | 0.79 | 1.8% |
| MSC Industrial Direct Co. Inc. MSM | $6.3 billion | 28.47 | 15.6% | 8.0% | 6.4% | 0.33 | 3.1% |
| Ingram Micro Holding Corp. INGM | $6.0 billion | 12.85 | 10.6% | 1.8% | 14.8% | 0.89 | 1.3% |
| LKQ Corp. LKQ | $5.1 billion | 20.06 | 4.0% | 4.8% | -1.4% | 0.59 | 6.0% |
| SiteOne Landscape Supply, Inc. SITE | $4.9 billion | 29.58 | 9.9% | 5.5% | 2.9% | 0.28 | n/a |
| Chefs' Warehouse, Inc. CHEF | $4.2 billion | 44.55 | 14.9% | 4.1% | 11.5% | 1.06 | n/a |
| Ashland Inc. ASH | $3.5 billion | 67.14 | 2.7% | 7.4% | -1.4% | 0.73 | 2.2% |
| Seaboard Corp. SEB | $3.4 billion | 6.14 | 10.0% | 2.6% | 7.0% | 0.30 | 0.3% |
| Hawkins Inc. HWKN | $3.1 billion | 36.66 | 15.2% | 11.1% | 9.0% | 0.41 | 0.5% |
| Central Garden & Pet Co. CENT | $3.0 billion | 17.82 | 9.5% | 8.1% | -1.2% | 0.68 | n/a |
| Resideo Technologies, Inc. REZI | $2.9 billion | 8.58 | 14.2% | 6.9% | 3.4% | 1.20 | n/a |
| United Natural Foods Inc. UNFI | $2.7 billion | 33.79 | 5.2% | 0.7% | -2.0% | 0.96 | n/a |
| Central Garden & Pet Co. CENTA | $2.6 billion | 15.23 | 9.5% | 8.1% | -1.2% | 0.68 | n/a |
| Boise Cascade Co. BCC | $2.4 billion | 20.59 | 5.9% | 2.8% | 1.2% | 0.22 | 1.3% |
| Eplus Inc. PLUS | $2.4 billion | n/a | n/a | n/a | n/a | 0.00 | 0.8% |
| DXP Enterprises Inc. DXPE | $2.2 billion | 23.34 | 17.3% | 8.9% | 12.9% | 1.44 | n/a |
| PC Connection Inc. CNXN | $2.0 billion | 19.54 | 10.5% | 4.1% | 9.5% | 0.00 | 0.9% |
| Vestis Corp. VSTS | $1.9 billion | n/a | -0.6% | 3.6% | -0.4% | 1.24 | 0.2% |
| Andersons, Inc. ANDE | $1.9 billion | 9.26 | 15.0% | n/a | -4.3% | 0.80 | 1.5% |
| World Kinect Corp. WKC | $1.8 billion | n/a | -13.1% | -0.1% | 21.1% | 0.54 | 2.4% |
| Global Industrial Co. GIC | $1.8 billion | 19.33 | 25.9% | 8.3% | 10.2% | 0.00 | 2.4% |
| Distribution Solutions Group, Inc. DSGR | $1.6 billion | 145.62 | 1.7% | 3.5% | 6.6% | 1.14 | n/a |
| Herbalife Ltd. HLF | $1.6 billion | 9.10 | n/a | 9.6% | 6.4% | n/a | n/a |
| Global Partners LP GLP | $1.5 billion | n/a | n/a | 1.5% | 29.5% | n/a | n/a |
| Ryerson Holding Corp. RYZ | $1.4 billion | n/a | 1.1% | 1.0% | 53.2% | 0.77 | 2.7% |
| Gold.com, Inc. GOLD | $1.1 billion | 12.50 | 10.1% | n/a | 110.1% | 0.00 | 2.1% |
| Willis Lease Finance Corp. WLFC | $990 million | 13.58 | 10.8% | 11.3% | 20.1% | 3.46 | 0.8% |
| Universal Corp. UVV | $982 million | n/a | -0.2% | 4.2% | -9.4% | 0.86 | 8.4% |
| Scansource, Inc. SCSC | $869 million | 13.38 | 7.4% | 2.5% | 14.8% | 0.36 | n/a |
| CrossAmerica Partners LP CAPL | $756 million | 15.97 | n/a | 2.7% | 9.1% | n/a | n/a |
| Climb Global Solutions, Inc. CLMB | $740 million | 30.76 | 17.7% | 4.0% | 24.2% | 0.00 | 0.4% |
| Weyco Group Inc. WEYS | $586 million | 14.70 | 15.0% | 17.1% | 1.5% | 0.00 | 5.1% |
| BlueLinx Holdings Inc. BXC | $476 million | n/a | -0.7% | 1.2% | 4.2% | 0.48 | n/a |
| L.B. Foster Co. FSTR | $415 million | 30.98 | 7.4% | 4.4% | 15.8% | 0.15 | n/a |
| Aspen Aerogels Inc. ASPN | $408 million | n/a | -70.6% | -59.3% | -39.3% | 0.46 | n/a |
| Sempreon, Inc. MGPI | $368 million | n/a | -42.0% | -57.2% | -15.9% | 0.57 | 2.8% |
| Richardson Electronics, Ltd. RELL | $229 million | 30.25 | 5.0% | 4.4% | 13.9% | 0.00 | n/a |
| AerSale Corp. ASLE | $219 million | n/a | -4.6% | -3.9% | -4.4% | 0.40 | n/a |
| NU Skin Enterprises, Inc. NUS | $199 million | n/a | -42.8% | -2.0% | -15.3% | 0.37 | 5.9% |
| Alta Equipment Group Inc. ALTG | $193 million | n/a | n/a | 0.9% | -1.8% | n/a | 1.9% |
| Arko Petroleum Corp. APC | $187 million | n/a | n/a | n/a | n/a | 0.76 | n/a |
| Hudson Technologies Inc. HDSN | $176 million | n/a | -0.5% | 0.4% | 2.3% | 0.00 | n/a |
| HF Foods Group Inc. HFFG | $80 million | n/a | -16.7% | -2.8% | 2.8% | 0.86 | n/a |
| Capstone Holding Corp. CAPS | $29 million | n/a | -177.9% | -17.2% | 38.9% | 2.05 | n/a |
4 companies share its SEC industry code (Wholesale-Drugs, Proprietaries & Druggists' Sundries); the rest are the names nearest in size in its wider industry, Wholesale, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read more
By market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.The public record on CAH
| Dividends | $491.0 million paid in cash dividends in FY2026 |
| Filings | 20 in twelve months: 10 current reports (8-K), about 7 regulation FD disclosure; 4 results of operations; 3 officer or director change; 1 material agreement; 1 termination of a material agreement |
| Planned insider sales | 11 Form 144 notices in twelve months, $70.5 million; latest 19 August 2026 |
| Options tape | put/call 0.91 by open interest at the 6 November 2026 close; the straddle prices a 3.7% move to 13 November 2026 |
| 13F holders | 1,506 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc. |
| Insider trading | 35 sales and 0 purchases on Form 4 in twelve months |
| Congress | 0 House trades disclosed in six months |
| Short interest | 7.7 million shares short, 4.99 days to cover at 15 October 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked |
Filings
| Filing | Period | Filed | Where |
|---|---|---|---|
| 10-Q | 30 September 2026 | 5 November 2026 | EDGAR |
| 10-K | 30 June 2026 | 11 August 2026 | EDGAR |
| 10-Q | 31 March 2026 | 30 April 2026 | EDGAR |
| 10-Q | 31 December 2025 | 5 February 2026 | EDGAR |
| 10-Q | 30 September 2025 | 30 October 2025 | EDGAR |
| 10-K | 30 June 2025 | 12 August 2025 | EDGAR |
| 10-Q | 31 March 2025 | 1 May 2025 | EDGAR |
| 10-Q | 31 December 2024 | 30 January 2025 | EDGAR |
| 10-Q | 30 September 2024 | 1 November 2024 | EDGAR |
| 10-K | 30 June 2024 | 14 August 2024 | EDGAR |
Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.